Core Viewpoint - The article discusses the advancements in in vivo CAR-T cell therapy, particularly focusing on a new type of lipid nanoparticle (LNP) that does not require antibody modification, which enhances the delivery of circRNA-based CAR-T cells for treating inflammatory aging diseases [1][2][3][5]. Group 1: In Vivo CAR-T Therapy Advantages - In vivo CAR-T therapy, based on mRNA, offers significant advantages over traditional ex vivo CAR-T therapy, especially in treating inflammatory aging diseases [6][14]. - The transient expression of in vivo CAR-T cells may be beneficial for inflammatory aging, contrasting with its potential drawbacks in solid tumor treatments [6][14]. Group 2: Research Innovations - The research team developed a novel type of LNP inspired by cardiolipin, which enhances T cell targeting without the need for antibody modification [8][15]. - The study demonstrated that the CAMP lipid increases the stiffness and phase separation of LNPs, improving T cell uptake [9][15]. Group 3: CircRNA Utilization - The research utilized circRNA to modify CAR mRNA, enhancing its stability and reducing cytotoxicity, which prolongs CAR protein expression in vivo [10][15]. - The encapsulation of CAR mRNA targeting uPAR in PL40-LNP provides a proof of concept for treating liver fibrosis and rheumatoid arthritis [11][12]. Group 4: Clinical Implications - The study highlights the potential of non-antibody targeting strategies in developing in vivo CAR-T therapies for clearing senescent cells associated with inflammatory aging diseases [17].